Az To File Triple Combination Therapy For Copd | Latest News RSS feed

Az To File Triple Combination Therapy For Copd - Latest News


AZ prepares to file COPD triple, taking on rival GSK

AstraZeneca has said it is ready to file for approval of its chronic obstructive pulmonary disease (COPD) triple therapy before the end ... reducing attacks by 52% compared to AZ’s LAMA/LABA combinati... read more

AZ to file triple combination therapy for COPD

Global Medicines at AZ, said: “We are encouraged by the results of the KRONOS trial which demonstrate PT010’s efficacy in improving lung function and its potential value as a triple combination therap... read more

Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD

This combination medicine will be delivered once daily in the Ellipta dry powder inhaler. Typically, the ICS/LAMA/LABA amalgamation for advanced COPD is ... announced filing of a regulatory submission ... read more

Looking for another news?


GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD

--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing ... a maintenance treatment to relieve symptoms of adult patients with COPD. It is b... read more


AZ boosted by COPD triple inhaler results

AZ’s single inhaler, PT010, showed statistically significant improvement in eight of nine lung ... and could file in the US and Europe next year. GlaxoSmithKline’s Trelegy is approved in the EU and US ... read more

How Will GlaxoSmithKline's Triple Therapy Combination Perform In The Market?

Potential Market Opportunity 18 percent of the COPD patients on treatment ... How much market share can GSK's triple therapy combination get ? GSK's closed triple therapy combination is expected to be ... read more

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

VX-445 triple combination therapy had an acceptable adverse ... University Medical Center, Tucson, AZ (C.D.); Universitätsmedizin Berlin and Berlin Institute of Health, Berlin, and the German Center f... read more

GSK files first application for triple COPD therapy

GlaxoSmithKline has submitted its three-in-one treatment for chronic obstructive pulmonary disease (COPD) in the US, more than a year earlier than planned. GSK had previously suggested it would file t... read more

POSITIVE PHASE III RESULTS FOR PT003 IN COPD

Today's results are also encouraging for the development of our investigative triple ... az-acquire-pearl). The company is focused on developing inhaled combination therapies for the treatment of high... read more

GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD

This is the first regulatory filing ... triple COPD therapy in a single inhaler. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said: “COPD is a debilitating lung disease affecting over five mil... read more

GSK files three-drug COPD inhaler in the US

GlaxoSmithKline and Innoviva have filed for approval in the US of a new once-daily, triple combination therapy for maintenance treatment of patients with chronic obstructive pulmonary disease ... A re... read more

Can Glaxo's COPD Triple Play A Solo Act?

In the race to launch a triple combination in chronic obstructive ... A second, larger Phase III trial called Impact asks whether treatment with FF/UMEC/VI is better at preventing exacerbations of COP... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us